Clinical Stage

Program 1

Unmet Need
  • Prevention of Myopia progression in children aged 7 to 17
Status
  • 12 years named patient use trial completed in Denmark
  • First therapeutic product globally for myopia control
Clinical Phase & IP
  • Phase 3 Clinical Trial in 2024
  • 20 Years IP
Molecule
  • 7 Methyl Xanthine

Program 2

Unmet Need
  • Reduce risk of ARDS Phase 1 progressing to Phase 2 in Covid-19 patients
  • Improve patient post Covid-19 recovery
Status
  • Investigator clinical trial in 15 patients in October 2020 completed successfully
Clinical Phase & IP
  • Phase 3 double-blind 180 clinical study completed
  • Patent filed September 2020
Molecule
  • Ketone Ester

Program 3

Unmet Need
  • Prevention of preterm birth in pregnant women
Status
  • Novel dosage form with 500% improved bio-availability
  • First product globally
Clinical Phase & IP
  • Patent filed September 2019
  • Phase 3 Clinical Trial 2024
Molecule
  • Algal DHA oil